--- title: "Anhui Fengyuan Pharmaceutical Co.,Ltd. (000153.SZ)" type: "quote" locale: "en" url: "https://longbridge.com/en/quote/000153.SZ.md" symbol: "000153.SZ" name: "Anhui Fengyuan Pharmaceutical Co.,Ltd." industry: "Pharmaceuticals" --- # Anhui Fengyuan Pharmaceutical Co.,Ltd. (000153.SZ) | Item | Detail | |------|--------| | Industry | Pharmaceuticals | | Location | CN Market | | Website | [www.bbcayy.com](https://www.bbcayy.com) | ## Company Profile Anhui Fengyuan Pharmaceutical Co., Ltd. researches and develops, produces, and sells medicines in China. The company also exports its products. Anhui Fengyuan Pharmaceutical Co., Ltd. ## Financial Score > *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.* > Updated: 2026-02-20T04:30:09.000Z **Overall: C (0.48)** **Industry**: Pharmaceuticals | Metric | Value | |--------|-------| | Industry Ranking | 169 / 222 | | Industry Median | C | | Industry Average | C | - **Style**: Value - Stocks where the company's main business is in a mature stage. - **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns. ### Score Analysis **Style Score**: #### Growth Score: | Indicator | Value | Rating | |-----------|-------|--------| | Revenue YoY | -3.81% | | | Net Profit YoY | -30.65% | | #### Value Score: | Indicator | Value | Rating | |-----------|-------|--------| | P/B Ratio | 1.45 | | | Dividend Ratio | 1.53% | | **Size Score**: #### Market Cap Score: | Indicator | Value | Rating | |-----------|-------|--------| | Market Cap | 3.04B | | #### Revenue Score: | Indicator | Value | Rating | |-----------|-------|--------| | Revenue | 4.15B | | **Multi Score**: C #### Profit Score: C | Indicator | Value | Rating | |-----------|-------|--------| | ROE | 5.55% | C | | Profit Margin | 2.74% | C | | Gross Margin | 13.62% | D | #### Growth Score: D | Indicator | Value | Rating | |-----------|-------|--------| | Revenue YoY | -3.81% | D | | Net Profit YoY | -30.65% | D | | Total Assets YoY | 6.52% | B | | Net Assets YoY | 5.13% | B | #### Cash Score: B | Indicator | Value | Rating | |-----------|-------|--------| | Cash Flow Margin | 3644.77% | A | | OCF YoY | -3.81% | D | #### Operating Score: B | Indicator | Value | Rating | |-----------|-------|--------| | Turnover | 0.86 | B | #### Debt Score: D | Indicator | Value | Rating | |-----------|-------|--------| | Gearing Ratio | 57.21% | D | ```chart-data:radar { "title": "Longbridge Financial Score - Anhui Fengyuan Pharmaceutical Co.,Ltd.", "chart_type": "radar", "dimensions": [ { "name": "Profit", "grade": "C", "indicators": [ { "name": "ROE", "value": "5.55%", "rating": "C" }, { "name": "Profit Margin", "value": "2.74%", "rating": "C" }, { "name": "Gross Margin", "value": "13.62%", "rating": "D" } ] }, { "name": "Growth", "grade": "D", "indicators": [ { "name": "Revenue YoY", "value": "-3.81%", "rating": "D" }, { "name": "Net Profit YoY", "value": "-30.65%", "rating": "D" }, { "name": "Total Assets YoY", "value": "6.52%", "rating": "B" }, { "name": "Net Assets YoY", "value": "5.13%", "rating": "B" } ] }, { "name": "Cash", "grade": "B", "indicators": [ { "name": "Cash Flow Margin", "value": "3644.77%", "rating": "A" }, { "name": "OCF YoY", "value": "-3.81%", "rating": "D" } ] }, { "name": "Operating", "grade": "B", "indicators": [ { "name": "Turnover", "value": "0.86", "rating": "B" } ] }, { "name": "Security", "grade": "D", "indicators": [ { "name": "Gearing Ratio", "value": "57.21%", "rating": "D" } ] } ] } ``` ### Peer Comparison | Rank | Name | Profit | Growth | Operation | Security | Cash | Rating | |------|------|--------|--------|-----------|----------|------|--------| | 01 | Allist (SH.688578) | A | A | B | A | B | A | | 02 | Xingqi Pharmaceutical (SZ.300573) | A | A | A | B | B | A | | 03 | Hengrui Pharma (SH.600276) | A | B | C | A | B | B | | 04 | Yunnan Baiyao (SZ.000538) | B | C | B | B | C | B | | 05 | Salubris (SZ.002294) | B | B | C | A | B | B | ## Valuation Analysis | Metric | Current | Industry Ranking | High | Median | Low | |--------|---------|-----------------|------|--------|-----| | PE (TTM) | 26.74 | 64/222 | 26.74 | 22.00 | 18.09 | | PB | 1.45 | 27/222 | 1.50 | 1.45 | 1.39 | | PS (TTM) | 0.73 | 4/222 | 0.77 | 0.73 | 0.67 | | Dividend Yield | 1.53% | 83/222 | 1.76% | 1.54% | 1.48% | ## References - [Company Overview](https://longbridge.com/en/quote/000153.SZ/overview.md) - Shareholders, executives, business segments - [Financials](https://longbridge.com/en/quote/000153.SZ/norm.md) - Income statement, balance sheet, cash flow, distribution plan - [Topics & Discussions](https://longbridge.com/en/quote/000153.SZ/topics.md) - Community topics and discussions --- > **Disclaimer**: This article is for reference only and does not constitute any investment advice.